Hyperpigmentation Disorder Treatment Global Market Report 2024

The hyperpigmentation disorder treatment market has grown strongly in recent years. It will grow from $5.3 billion in 2023 to $5.69 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The expansion observed during the historical period can be attributed to factors such as clinical trials and research in the field, advances in chemical peels technology, a cultural shift towards skincare, an emphasis on non-invasive treatment options, and an increasing demand for natural products in hyperpigmentation disorder treatment.

The hyperpigmentation disorder treatment market is expected to see strong growth in the next few years. It will grow to $7.73 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The anticipated growth in the forecast period can be attributed to a focus on non-invasive treatments, increased awareness of skincare, the adoption of telemedicine and virtual consultations, regulatory support and approvals for hyperpigmentation disorder treatments, and the availability of personalized treatment options. Major trends expected in the forecast period include the development of innovative topical formulations, advancements in laser technologies, a focus on combination therapies, personalized treatment approaches, and a rising demand for natural products in the hyperpigmentation disorder treatment market.

The expected increase in the prevalence of pigmentation disorders is anticipated to fuel the growth of the hyperpigmentation disorders treatment market. Pigmentation disorders encompass various conditions affecting the coloration of the skin, hair, and eye iris, typically resulting from issues with melanin, the pigment produced by melanocytes. Treatment options for hyperpigmentation disorders vary based on the underlying cause and severity, with mild cases often managed through over-the-counter topical creams containing ingredients such as azelaic acid, cysteamine cream, vitamin C, and hydroquinone, known for their skin-lightening properties. For example, a report from the Centers for Disease Control (CDC) in March 2023 highlighted an increase in Candida auris cases in the US from 476 in 2019 to 1,471 in 2021. Additionally, the National Psoriasis Foundation reported in December 2022 that psoriasis affects 125 million people globally, representing 2 to 3 percent of the overall population. The rise in pigmentation disorders' prevalence is expected to drive the growth of the hyperpigmentation disorders treatment market.

The growth of the hyperpigmentation disorder treatment market is further propelled by increasing cosmetic concerns. Cosmetic concerns refer to worries or considerations related to one's physical appearance, beauty, or aesthetics. The rising focus on cosmetic concerns encourages individuals to seek hyperpigmentation disorder treatments, fostering innovation in the cosmetic and dermatological industries and enhancing the overall patient experience. Reports from the International Society of Aesthetic Plastic Surgery (ISAPS) in September 2023 revealed that plastic surgeons are expected to perform over 14.9 million surgical and 18.8 million non-surgical operations in 2022, reflecting an overall increase of 11.2%. The heightened emphasis on cosmetic concerns is a significant driver behind the growth of the hyperpigmentation disorder treatment market.

A prominent trend in the hyperpigmentation disorders treatment market is the focus on product innovation by major companies striving to bolster their positions and gain a competitive advantage. An illustration of this trend is evident in the actions of Uniza Healthcare, an India-based pharmaceutical company, which, in October 2021, introduced a groundbreaking treatment product named Vitellus. This lotion, comprising a distinctive blend of EUK-134, Greyverse, and Melitane GL 200, not only stimulates melanin growth but also addresses skin pigmentation, hair follicle pigmentation, and acts as a potent antioxidant.

Major players in the hyperpigmentation disorder treatment market are strategically launching innovative products to meet the growing demand for effective and safe hyperpigmentation treatment. A noteworthy example is the Cyspera Intensive System, unveiled by Cyspera (Scientis SA), a Switzerland-based dermatology company, in June 2021. This revolutionary three-step hyperpigmentation treatment is meticulously designed to target persistent brown patches and dark spots. The system features a proprietary Cysteamine Isobionic-Amide Complex, a patented melanosomal transfer inhibitor within the vitamin B3 family. This complex collaborates synergistically with cysteamine to deliver three powerful effects. In essence, the Cyspera Intensive System emerges as a promising new option for hyperpigmentation treatment, ensuring safety and efficacy for all skin types without harsh chemicals.

In December 2021, DermBiont, Inc., a US-based biotechnology company, executed the acquisition of Chroma Dermatology. The undisclosed amount spent on this acquisition enabled DermBiont to diversify its drug pipeline, incorporating expertise in managing various skin hyperpigmentation conditions such as melasma and solar lentigos. This expansion complements DermBiont's existing focus on conditions such as seborrheic keratosis, atopic dermatitis, seborrheic dermatitis, and acne. Chroma Dermatology, as a US-based clinical-stage biotechnology company, became an integral part of DermBiont's comprehensive approach to dermatological solutions.

Major companies operating in the hyperpigmentation disorder treatment market report are Vivier Pharma, Obagi Cosmeceuticals LLC, RXi Pharmaceuticals Corporation, EpiPharm AG, Laboratories Pierre Fabre, SkinCeuticals, Galderma S.A., Allergan PLC., Bayer AG, Lumenis Be Ltd., Aerolase Corporation, Candela Corporation, Cynosure, PCA Skin, Episciences Inc., La Roche-Posay, L'Oréal S.A., Pierre Fabre Laboratories, Alvogen Inc., Clinuvel Pharmaceuticals Ltd., Clarify Medical Inc., Incyte Corporation, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries, SkinMedica Inc., Neutrogena Corporation, Paula's Choice Inc., ZO Skin Health Inc., Estée Lauder Companies Inc.

North America was the largest region in the hyperpigmentation disorders treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global hyperpigmentation disorder treatment market report during the forecast period. The regions covered in the hyperpigmentation disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hyperpigmentation disorder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Treatment types in the hyperpigmentation disorder treatment market include cosmeceuticals, laser therapy, chemical peels, microdermabrasion, phototherapy, and other treatments. Cosmeceuticals are cosmetics with active ingredients that may have therapeutic effects on the skin. They are utilized to treat various conditions, including melasma, post-inflammatory hyperpigmentation, solar lentigines, and other indications. These treatments are administered by various end-users, including hospitals, esthetic clinics, dermatology centers, and other healthcare facilities.

The hyperpigmentation disorder treatment market research report provides hyperpigmentation disorder treatment optical components market statistics, including hyperpigmentation disorder treatment optical components industry global market size, regional shares, competitors with a hyperpigmentation disorder treatment optical components market share, detailed hyperpigmentation disorder treatment optical components market segments, market trends and opportunities, and any further data you may need to thrive in the hyperpigmentation disorder treatment optical components industry. This hyperpigmentation disorder treatment optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hyperpigmentation disorder treatment market consists of revenues earned by entities by providing hyperpigmentation disorder treatment services such as microdermabrasion and tropical treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The hyperpigmentation disorder treatment market also includes sales of serums, creams, gels or lotions formulated for the treatment of hyperpigmentation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.